Singapore-based biopharma firm ASLAN Pharmaceuticals has filed for a proposed initial public offering (IPO) in the US to raise capital for clinical development of its products and trials.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
